GlassScriptPhysician profile
Jason P Gonsky
NPI 1184835035
$454.66
in general payments reported to CMS, 2019-2025
11 companies · $46.20 in 2025
The $46.20 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.79 · 2021: $52.91 · 2022: $86.38 · 2023: $16.70 · 2024: $183 · 2025: $46.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $109.44 | 2021-2024 | Opdivo |
| Taiho Oncology, INC. | $105.85 | 2022-2025 | |
| Gilead Sciences, INC. | $69.79 | 2019 | |
| Astellas Pharma US INC | $29.98 | 2023-2024 | Xtandi |
| Recordati_rare_diseases_inc. | $24.16 | 2024 | Sylvant |
| Daiichi Sankyo INC. | $24.08 | 2024 | Enhertu |
| Springworks Therapeutics, INC. | $22.92 | 2025 | Ogsiveo |
| Celgene Corporation | $21.16 | 2024 | Reblozyl |
| Incyte Corporation | $17.99 | 2021 | |
| Lilly USA, LLC | $17.23 | 2024 | Verzenio, Retevmo, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Gonsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.